Page 21 - Harvard Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cytek Biosciences (NASDAQ:CTKB – Get Rating) and Harvard Bioscience (NASDAQ:HBIO – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations. Analyst Recommendations This is a summary of current recommendations […]

/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in...

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Wall Street brokerages predict that Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating) will announce $29.10 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Harvard Bioscience’s earnings, with the lowest sales estimate coming in at $29.00 million and the highest estimate coming in at $29.20 million. […]